Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham: Safety: Development of endophthalmitis at 1 year
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty). Complement inhibitors for age‐related macular degeneration (2023) · Cochrane Headline outcomes only | RR 4.77 [0.55, 41.68] | 3 studies · 997 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.